Lancet HIV

Article	Citations
Tackling cancer risk in adolescents and young adults with HIV	221
Invest in HIV now to reap future rewards	192
Inherited fear: 40 years of HIV/AIDS in the UK	147
The time to end the war on drugs is long overdue	137
Rapid access to antiretroviral therapy, receipt of naltrexone, and strengths-based case management versus standard of care for HIV viral load suppression in people with HIV who inject drugs in Russia	129
Lenacapavir plus two bNAbs: feasible, with some caveats	120
Call for justice-informed HIV cure trials with ATIs	119
A new initiative to track HIV resource allocation	107
The power of peers at prison exit	101
Improving outcomes for children in families with HIV	101
Trauma-informed HIV prevention for forcibly displaced adolescents and young adults	99
Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trial	90
Highlights of HIV Drug Therapy 2022	90
Changes in bodyweight after initiating antiretroviral therapy close to HIV-1 seroconversion: an international cohort collaboration	82
Optimising HIV spending in eastern Europe and central Asia	73
Reflections on a decade of The Lancet HIV	72
Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind,	72
PEPFAR reauthorisation hangs in the balance	72
UNAIDS strategy aligns HIV priorities with development goals	71
Empowering women: addressing HIV vertical transmission in the Philippines	70
Dolutegravir for children with HIV-associated tuberculosis	69
Gone but not forgotten	69
Zvandiri—when medicines alone are not enough	67
How much could long-acting PrEP cost in South Africa?	65
AIDS activism from the beginning	59

Combination HIV prevention reduces orphanhood in Uganda	55
Helping hospitals heal people with HIV and tuberculosis	55
Community mobilisation to achieve HIV testing and care goals	52
Evidence supports use of on-demand PrEP for HIV prevention	51
HIV and mental health services for female sex workers	51
Transitioning youth living with HIV to adult HIV care	50
The Australian AIDS crisis through the eyes of volunteers	47
Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial	45
Lymphomas included in the AIDS case definition: an update 30 years later	44
HIV-related CNS infections: translating DREAMM into reality	44
The Háttér Society: supporting LGBTQ people in Hungary	41
Anything but pro-life	41
Ageing with HIV: is the virus or the treatment guilty?	41
UK HIV transmission drops in the wake of COVID-19	41
Marking 40 years of the HIV/AIDS response	40
Integrase strand-transfer inhibitor use and cardiovascular events in adults with HIV: an emulation of target trials in the HIV-CAUSAL Collaboration and the Antiretroviral Therapy Cohort Collaboration	40
How do we prevent anal cancer in people living with HIV?	37
Supporting Poland's LGBT+ community through thick and thin	36
Argentina updates HIV laws	36
Effects of long-term antiretroviral therapy in reproductive-age women in sub-Saharan Africa (the PEPFAR PROMOTE study): a multi-country observational cohort study	34
A career dedicated to public service	34
Expanding options of child-friendly, single-tablet regimens for young children with HIV	33
Innovations, adaptations, and accelerations in the delivery of HIV services during COVID-19	32
Enhancing HIV care with incentives: one size does not fit all	32
Successes and challenges in Thailand's HIV response	32
Highlights from CROI 2024	32
Bacterial sexually transmitted infections among men who have sex with men and transgender women using oral pre-exposure prophylaxis in Latin America (ImPrEP): a secondary analysis of a prospective, op	31
Navigating the AIDS crisis with open hearts	30
Lung cancer in people living with HIV	30
HIV PrEP and viral hepatitis: a unique opportunity for integration	30
HIV viral suppression is key to healthy longevity	29
Highlights of the 19th European AIDS Conference	28
Lenacapavir: an attractive option, but proceed with caution	28
A pioneer for sexuality, race, and identity	28
Ending HIV in Chicago by 2030	27
LVCT Health: implementing PrEP in Kenya	27
Transplant donation without discrimination	27
Towards no missed opportunities: the experience of 56 Dean Street	27
Insights on COVID-19 mortality and HIV from South Africa	26
Drug-level feedback counselling: modest support to PrEP adherence	26
Checklist for studies of HIV drug resistance prevalence or incidence: rationale and recommended use	25
Gender-affirming HIV care as a tool to end the HIV epidemic	24
PrEParing for choice in a new era of HIV prevention	24
ART and cardiovascular-disease risk in people with HIV	24
Immunological and virological findings in a patient with exceptional post-treatment control: a case report	22
HIV and COVID-19: juxtaposition of two pandemics	22
Planning for PrEP: are national surveillance data sufficient?	22
Tracking elimination of HIV transmission in men who have sex with men in England: a modelling study	22
Safety and pharmacokinetics of escalating doses of neutralising monoclonal antibody CAP256V2LS administered with and without VRC07-523LS in HIV-negative women in South Africa (CAPRISA 012B): a phase 1	21
Estimated life expectancy gains with antiretroviral therapy among adults with HIV in Latin America and the Caribbean: a multisite retrospective cohort study	21

Low-cost urine tenofovir assay to triage dolutegravir resistance testing	20
Multilevel interventions for young people with HIV	20
Prioritise people with HIV for COVID-19 vaccination	20
Trends in HIV prevalence, incidence, and progress towards the UNAIDS 95-95-95 targets in Malawi among individuals aged 15–64 years: population-based HIV impact assessments, 2015−16 and 2020−21	20
Emergent HIV drug resistance in non-inferiority trials	20
Free HIV self-test for identification and linkage to care of previously undetected HIV infection in men who have sex with men in England and Wales (SELPHI): an open-label, internet-based, randomised c	20
Increased risk of mental illness in people with HIV	20
Implied consent for HIV testing in the UK: time for a new approach?	19
Optimising anal cancer screening through risk stratification	19
Subnational mapping of HIV incidence and mortality among individuals aged 15–49 years in sub-Saharan Africa, 2000–18: a modelling study	19
Experiences of HIV among global Indigenous populations through the lens of the UN Declaration on the Rights of Indigenous Peoples	18
Voucher incentives to improve viral suppression among HIV-positive people who inject drugs and men who have sex with men in India: a cluster randomised trial	18
Health impact, budget impact, and price threshold for cost-effectiveness of lenacapavir for HIV pre-exposure prophylaxis in eastern and southern Africa: a modelling analysis	18
Efficiency of 6-month PrEP dispensing with HIV self-testing in Kenya: an open-label, randomised, non-inferiority, implementation trial	18
Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial	17
HIV incidence estimation among female sex workers in South Africa: a multiple methods analysis of cross-sectional survey data	17
Rates of viral suppression in a cohort of people with stable HIV from two community models of ART delivery versus facility-based HIV care in Lusaka, Zambia: a cluster-randomised, non-inferiority trial	17
Effect of climate change on the HIV response	17
Dolutegravir once daily with rifampicin for HIV and tuberculosis	17
Intertwined epidemics: progress, gaps, and opportunities to address intimate partner violence and HIV among key populations of women	17
Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analy	16
Improvements in transition times through the HIV cascade of care among gay and bisexual men with a new HIV diagnosis in New South Wales and Victoria, Australia (2012–19): a longitudinal cohort study	16
Thailand's commitment to support community-led HIV services	16
Scaling up access to HIV pre-exposure prophylaxis (PrEP): should nurses do the job?	16
Are we ready for long-acting HIV treatment for adolescents?	16
Safety, adherence, and HIV-1 seroconversion among women using the dapivirine vaginal ring (DREAM): an open-label, extension study	16
All the viral loads we cannot see	16
The effects of cash transfer programmes on HIV/AIDS prevention and care outcomes: a systematic review and meta-analysis of intervention studies	15
Forgiveness of an intermittent HIV treatment strategy	15
Interventions to ensure access to and continuity of HIV care for international migrants: an evidence synthesis	15
Adoption of guidelines on and use of oral pre-exposure prophylaxis: a global summary and forecasting study	15
Correction to Lancet HIV 2023; 10: e424–26	15
Clinical features of, and risk factors for, severe or fatal COVID-19 among people living with HIV admitted to hospital: analysis of data from the WHO Global Clinical Platform of COVID-19	15
Tailoring care for frail and lonely older people with HIV in Canada: a cross-sectional study	15
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 and hepatitis B coinfection (ALLIANCE): a dou	15
Correction to Lancet HIV 2022; 9: e791–800	15
Antiretrovirals and obesity	14
Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study	14
Correction to Lancet HIV 2022; 9: e79–90	14
Correction to Lancet HIV 2023; 10: e713–22	14
Correction to Lancet HIV 2024; 11: e86–95	14
Prophylactic HIV-1 vaccine trials: past, present, and future	14
Epigenetic age acceleration changes 2 years after antiretroviral therapy initiation in adults with HIV: a substudy of the NEAT001/ANRS143 randomised trial	14
Risk estimation in HIV reveals our usual blind spots	13
Effect of screening for Neisseria gonorrhoeae and Chlamydia trachomatis on incidence of these infections in men who have sex with men and transgender women taking HIV pre-exposure prophylaxis (the Gon	13
HIV care cascade and associated factors among men who have sex with men, transgender women, and genderqueer individuals in Zimbabwe: findings from a biobehavioural survey using respondent-driven sampl	13
Improving quality of interpersonal care in HIV programmes	13
Safety and immunogenicity of a polyvalent DNA–protein HIV vaccine with matched Env immunogens delivered as a prime–boost regimen or coadministered in HIV-uninfected adults in the USA (HVTN 124): a pha	13
All roads lead to Westminster: the infected blood scandal	13
Correction to Lancet HIV 2024; 11: e233–44	13
The long wait for long-acting HIV prevention and treatment formulations	13
International Women's Day—how can I help?	12
HIV/AIDS cast a dark shadow on 1980s London gay culture	12
Where does doravirine fit in current antiretroviral therapy?	12
Imperfect progress: treatment options for opioid dependence	11
A public health approach to drug use crucial to ending AIDS	11
Projected outcomes of universal testing and treatment in a generalised HIV epidemic in Zambia and South Africa (the HPTN 071 [PopART] trial): a modelling study	11
Ending HIV in the UK	11
Improving outcomes after hospitalisation in people with HIV	11
Africa and AIDS: still much work to be done	11
UK and US militaries update HIV policies	10
Home delivery of ART: could this be a reality in South Africa?	10
Real-world safety of pre-exposure prophylaxis for HIV	10
Game-changing study of second-line HIV treatment	10
Moving forward with dolutegravir in children weighing less than 20 kg	10
AIDS activism through art	10
Innovation is important, but so is access	9
Viral suppression and self-reported ART adherence after 3 years of universal testing and treatment in the HPTN 071 (PopART) community-randomised trial in Zambia and South Africa: a cross-sectional ana	9
Optimising oral PrEP while awaiting long-acting cabotegravir	9
PrEP for men who have sex with men in Africa	9
Unheard testimony	9
Tuberculosis screening among HIV-positive inpatients: a systematic review and individual participant data meta-analysis	9
Tangerine Clinic: championing transgender health care	9
Comparison of index-linked HIV testing for children and adolescents in health facility and community settings in Zimbabwe: findings from the interventional B-GAP study	9
COVID-19 antivirals must not affect HIV drug supply	9
The contribution of intimate partner violence to vertical HIV transmission: a modelling analysis of 46 African countries	9
Brain not exempt from social determinants of health	8
Bridging accessibility gaps in HIV prevention	8
Reassessing oral lead-in for injectable long-acting HIV therapy	8
Thank you to The Lancet HIV's statistical and peer reviewers in 2022	8

Equitable access to PrEP is essential to reap its benefits	8
Menopausal hormone therapy for women living with HIV	8
Outdated attitudes to HIV must change	8
Monkeypox vaccination—an opportunity for HIV prevention	8
PrEP empowering female sex workers in Kenya	8
Longitudinal trends in causes of death among adults with HIV on antiretroviral therapy in Europe and North America from 1996 to 2020: a collaboration of cohort studies	7
The effect of providing women sustained access to HIV self-tests on male partner testing, couples testing, and HIV incidence in Kenya: a cluster-randomised trial	7
Potential population-level effects of HIV self-test distribution among key populations in Côte d'Ivoire, Mali, and Senegal: a mathematical modelling analysis	7
Long-term protection from HIV infection with oral HIV pre-exposure prophylaxis in gay and bisexual men: findings from the expanded and extended EPIC-NSW prospective implementation study	7
To give or not to give: what is the evidence?	7
Gradual improvements in HIV outcomes for African GBMSM	7
A second decade of PrEP	7
Variations in the characteristics and outcomes of children living with HIV following universal ART in sub-Saharan Africa (2006–17): a retrospective cohort study	7
Putting people first in communication about HIV	7
Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial	7
Implementation of HIV prevention strategies globally	7
Safety and efficacy of iron supplementation with 3 months of daily ferrous sulphate in children living with HIV and mild-to-moderate anaemia in Uganda: a double-blind, randomised, placebo-controlled t	7
Equitable access to long-acting PrEP on the way?	7
Suicide prevention research is crucial to achieving health equity for people with HIV	6
Defining principles for a choice-based approach to HIV prevention	6
Social determinants of transgender women's health	6
Highlights of IAS 2023	6
Impact of universal testing and treatment on sexual risk behaviour and herpes simplex virus type 2: a prespecified secondary outcomes analysis of the HPTN 071 (PopART) community-randomised trial	6
Mexican perspective on the Mosaico HIV vaccine trial	6
HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis	6
Life-expectancy with HIV in Latin America and the Caribbean	6
Highlights of virtual CROI 2022	6
Observed CD4 counts at entry into HIV care and at antiretroviral therapy prescription by age in the USA, 2004–18: a cohort study	6
Perspectives on the use of modelling and economic analysis to guide HIV programmes in sub-Saharan Africa	6
Effectiveness of bi-monthly long-acting injectable cabotegravir and rilpivirine as maintenance treatment for HIV-1 in the Netherlands: results from the Dutch ATHENA national observational cohort	6
Stigma reduction is key to improving the HIV care continuum	6
Compelling evidence for unconditional shift to dolutegravir	6
Integration of sexual health and HIV services	6
Lessons from the HPTN 071 (PopART) trial	6
Ethical trial design for the future	6
SARS-CoV-2 immunity and HIV infection: total recall?	6
Gains and gaps: addressing HIV in diverse sex worker groups	6
Sex as a biological variable in HIV-1 and schistosome co-infection	6
Reducing HIV transmission in British Columbia, Canada	6
Reaching the third 95 using community ART delivery models	5
Analytical treatment interruption in children living with HIV: position statement from the EPIICAL consortium	5
Outcomes of people living with HIV after hospital discharge: a systematic review and meta-analysis	5
Fate of people with HIV in jeopardy in Ukraine	5
More evidence for worse COVID-19 outcomes in people with HIV	5
Living authentically despite prejudice and marginalisation	5
Person-centred care for older adults living with HIV in sub-Saharan Africa	5
Need for transgender-specific data from Asia	5
Cost-effectiveness of point-of-care testing with task-shifting for HIV care in South Africa: a modelling study	5
Non-suppressible viraemia during HIV-1 therapy: a challenge for clinicians	5
Refugees from Ukraine: children and adolescents with HIV in Germany	5
Disparities in approaches to ART access in Europe	5
Recent gay Black history in the UK	5
Pharmacokinetics and safety of coformulated bictegravir, emtricitabine, and tenofovir alafenamide in children aged 2 years and older with virologically suppressed HIV: a phase 2/3, open-label, single-	5
Tenofovir disoproxil fumarate withdrawal and cardiovascular risk	5
HIV targets unattainable with gender-based inequalities	5
Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1–2 trial	5
Time to tackle late diagnosis	5
Response to Thailand's commitment to support community-led HIV services	5
Screening for chlamydia and incidence of symptomatic infections	5
What future for HIV vaccines?	5
Anti-LGBT laws continue to hinder the HIV response	5
Abacavir dosing in neonates from birth to 3 months of life: a population pharmacokinetic modelling and simulation study	4
Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study	4
Prioritising pleasure and correcting misinformation in the era of U=U	4
Expansion of PrEP and PEP services in China	4
Ensuring the right to health for migrants and refugees	4
HIV pre-exposure prophylaxis for men who have sex with men in west Africa: a multicountry demonstration study	4
UK emergency department testing for HIV expanded	4
Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study	4
HIV-1 reservoir size after neonatal antiretroviral therapy and the potential to evaluate antiretroviral-therapy-free remission (IMPAACT P1115): a phase 1/2 proof-of-concept study	4
HIV self-testing, PrEP, and drug resistance: some insights	4
Extreme weather events and disruptions to HIV services: a systematic review	4
Antiretroviral efficacy versus neurotoxicity	4
Trends and risk of lung cancer among people living with HIV in the USA: a population-based registry linkage study	4
Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial	4
Long-acting PrEP: new opportunities with some drawbacks	4
Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor ther	4
Primary HIV-1 infection in users of pre-exposure prophylaxis	4
HIV self-testing: from availability to strategic deployment	3
Pregnancy outcomes for new ART regimens	3
Mainline—confronting chemsex in the Netherlands	3
Conquering the AIDS establishment: Peter Staley's inside game	3
Approaching the asymptote	3
It is time to act on ageing	3
COP27 Climate Change Conference: urgent action needed for Africa and the world	3
Dolutegravir in late pregnancy: where to from here?	3
The Kirby Institute—ending HIV transmission in Australia	3
PEPFAR: promises and pitfalls	3
Call for abstracts: HIV and Healthy Longevity	3
Living longer with HIV: gains for some but not for all	3
Effect of UTT on viral suppression and ART adherence	3
A welcome like no other	3
Do not repeat mistakes from HIV in COVID-19 response	3
A trailblazer in art and activism	3
Mental health needs of adolescents with HIV in Africa – Authors' reply	3